摘要
摘要目的探讨奈达铂(NDP,商品名奥先达)联合替加氟(FT－２０７)治疗晚期头颈部癌的临床疗效及毒副反应发生情况.方法选择４７例晚期头颈部癌患者进行化疗,方案为第１天,奈达铂８０mg/m２,静脉滴注２小时以上,第１天－５天,替加氟５００mg/m２,静脉滴注８小时,每２８天为１个周期.结果４７例患者近期总有效率为４８．９％,初治２１例患者有效率为５７．１％,复治２６例患者有效率为４６．２％;毒副反应发生以骨髓抑制及消化道反应为主,其中白细胞下降者占６３．８％,血小板下降者５１．５％,各自３度、４度总发生率分别为８．５％和１４．９％,恶心、呕吐者４２．６％,无３度、４度反应发生.结论NDP联合FT－２０７治疗晚期头颈部癌的临床疗效显著,毒副反应可耐受.关键词晚期头颈部癌;奈达铂;替加氟ClinicalObservationofNedaplatinCombinedwithTegafurtoTreatAdvancedHeadandNeckCancerAbstractObjectivetodiscusstheclinicalefficacyandtoxicityofnedaplatincombinedwithtegafurtotreatpatientswithadvancedheadandneckcancer．Methods４７patientswithadvancedheadandneckneoplasmswerechosentreatedwithNDPatadoseof８０mg/m２intravenouslyatleast２hoursondlandFT－２０７atadoseof５００mg/m２for８hoursondl－d５,every２８daysasacycle．ResultsThetotalefficiencyof４７patientswas４８．９％,theefficiencywas５７．１％in２１patientswithnopriorhistoryofchemotherapy,theefficiencywas４６．２％in２６patientswhohadeverreceivedpostoperativeadjuvantchemotherapy;Themaintoxicitiesincludedmyelousuppressionandgastrointestinaltoxicities,areductioninwhitebloodcellsandplateletswere６３．８％and５１．５％respectively,３and４deＧgreeoccurrenceratewere８．５％and１４．９％．Nauseaandvomitingwas４２．６％,andtherewasno３and４degreeoccurrence．ConclusionNDPcombinedwithFT－２０７isKeeffyecwtiovredsandtolerableinthetreatmentofadvaneedheadandneckcancer．Advancedheadandneckcancer;NDP;FT－２０７中图分类号R７３９．９文献标识码B文章编号１００８－６３１５(２０１５)１２－１４２２－０１
出版日期
2015年12月22日（中国期刊网平台首次上网日期，不代表论文的发表时间）
